XPOVIO

XPOVIO- selinexor tablet, film coated
Karyopharm Therapeutics Inc.

1 INDICATIONS AND USAGE

1.1 Multiple Myeloma

XPOVIO in combination with dexamethasone is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody.

This indication is approved under accelerated approval based on response rate [see Clinical Studies (14.1)]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

1.2 Diffuse Large B-Cell Lymphoma

XPOVIO is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least 2 lines of systemic therapy.

This indication is approved under accelerated approval based on response rate [see Clinical Studies (14.2)]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

2 DOSAGE AND ADMINISTRATION

2.1 Recommended Dosage for Multiple Myeloma

The recommended dosage of XPOVIO is 80 mg taken orally on Days 1 and 3 of each week until disease progression or unacceptable toxicity. Administer dexamethasone 20 mg orally with each dose of XPOVIO on Days 1 and 3 of each week. For additional information regarding the administration of dexamethasone, refer to its prescribing information.

2.2 Recommended Dosage for Diffuse Large B-Cell Lymphoma

The recommended dosage of XPOVIO is 60 mg taken orally on Days 1 and 3 of each week until disease progression or unacceptable toxicity.

2.3 Recommended Monitoring for Safety

Monitor complete blood count (CBC) with differential, standard blood chemistries, body weight, nutritional status, and volume status at baseline and during treatment as clinically indicated. Monitor more frequently during the first three months of treatment [see Warning and Precautions (5.1, 5.2, 5.3, and 5.4)]. Assess the need for dosage modifications of XPOVIO for adverse reactions [see Dosage and Administration (2.5)].

2.4 Recommended Concomitant Treatments

Advise patients to maintain adequate fluid and caloric intake throughout treatment. Consider intravenous hydration for patients at risk of dehydration [see Warnings and Precautions (5.3, 5.4)].

Provide prophylactic antiemetics. Administer a 5-HT3 receptor antagonist and other anti-nausea agents prior to and during treatment with XPOVIO [see Warnings and Precautions (5.3)].

2.5 Dosage Modification for Adverse Reactions

Recommended XPOVIO dosage reduction steps are presented in Table 1.

Table 1: XPOVIO Dosage Reduction Steps for Adverse Reactions
Recommended Starting Dosage Multiple Myeloma Diffuse Large B-Cell Lymphoma
80 mg Days 1 and 3 of each week(160 mg total per week) 60 mg Days 1 and 3 of each week(120 mg total per week)
First Reduction 100 mg once weekly 40 mg Days 1 and 3 of each week(80 mg total per week)
Second Reduction 80 mg once weekly 60 mg once weekly
Third Reduction 60 mg once weekly 40 mg once weekly
Fourth Reduction Permanently discontinue Permanently discontinue

Recommended dosage modifications for hematologic adverse reactions in patients with multiple myeloma and DLBCL are presented in Table 2 and Table 3, respectively. Recommended dosage modifications for non-hematologic adverse reactions are presented in Table 4.

Table 2: XPOVIO Dosage Modification Guidelines for Hematologic Adverse Reactions in Patients with Multiple Myeloma
Adverse Reaction Occurrence Action
Thrombocytopenia [see Warning and Precautions (5.1)]
Platelet count 25,000 to less than 75,000/mcL Any
  • Reduce XPOVIO by 1 dose level (see Table 1).
Platelet count 25,000 to less than 75,000/mcL with concurrent bleeding Any
  • Interrupt XPOVIO.
  • Restart XPOVIO at 1 dose level lower (see Table 1) after bleeding has resolved.
  • Administer platelet transfusions per clinical guidelines.
Platelet count less than 25,000/mcL Any
  • Interrupt XPOVIO.
  • Monitor until platelet count returns to at least 50,000/mcL.
  • Restart XPOVIO at 1 dose level lower (see Table 1).
Neutropenia [see Warning and Precautions (5.2)]
Absolute neutrophil count of 0.5 to 1 x 109 /L without fever Any
  • Reduce XPOVIO by 1 dose level (see Table 1).
Absolute neutrophil count less than 0.5 x 109 /LOR febrile neutropenia Any
  • Interrupt XPOVIO.
  • Monitor until neutrophil counts return to 1 x 109 /L or higher.
  • Restart XPOVIO at 1 dose level lower (see Table 1).
Anemia
Hemoglobin less than 8 g/dL Any
  • Reduce XPOVIO by 1 dose level (see Table 1).
  • Administer blood transfusions per clinical guidelines.
Life-threatening consequences Any
  • Interrupt XPOVIO.
  • Monitor hemoglobin until levels return to 8 g/dL or higher.
  • Restart XPOVIO at 1 dose level lower (see Table 1).
  • Administer blood transfusions per clinical guidelines.
Table 3: XPOVIO Dosage Modification Guidelines for Hematologic Adverse Reactions in Patients with Diffuse Large B-Cell Lymphoma
Adverse Reaction Occurrence Action
Thrombocytopenia [see Warning and Precautions (5.1)]
Platelet count 50,000 to less than 75,000/mcL Any
  • Interrupt one dose of XPOVIO.
  • Restart XPOVIO at the same dose level.
Platelet count 25,000 to less than 50,000/mcL without bleeding 1st
  • Interrupt XPOVIO.
  • Monitor until platelet count returns to at least 50,000/mcL.
  • Reduce XPOVIO by 1 dose level (see Table 1).
Platelet count 25,000 to less than 50,000/mcL with concurrent bleeding Any
  • Interrupt XPOVIO.
  • Monitor until platelet count returns to at least 50,000/mcL.
  • Restart XPOVIO at 1 dose level lower (see Table 1), after bleeding has resolved.
  • Administer platelet transfusions per clinical guidelines.
Platelet count less than 25,000/mcL Any
  • Interrupt XPOVIO.
  • Monitor until platelet count returns to at least 50,000/mcL.
  • Restart XPOVIO at 1 dose level lower (see Table 1).
  • Administer platelet transfusions per clinical guidelines.
Neutropenia [see Warning and Precautions (5.2)]
Absolute neutrophil count of 0.5 to less than 1 x 109 /L without fever 1st occurrence
  • Interrupt XPOVIO.
  • Monitor until neutrophil counts return to 1 x 109 /L or higher.
  • Restart XPOVIO at the same dose level.
Recurrence
  • Interrupt XPOVIO.
  • Monitor until neutrophil counts return to 1 x 109 /L or higher.
  • Administer growth factors per clinical guidelines.
  • Restart XPOVIO at 1 dose level lower (see Table 1).
Absolute neutrophil count less than 0.5 x 109 /LOR Febrile neutropenia Any
  • Interrupt XPOVIO.
  • Monitor until neutrophil counts return to 1 x 109 /L or higher.
  • Administer growth factors per clinical guidelines.
  • Restart XPOVIO at 1 dose level lower (see Table 1).
Anemia
Hemoglobin less than 8 g/dL Any
  • Reduce XPOVIO by 1 dose level (see Table 1).
  • Administer blood transfusions per clinical guidelines.
Life-threatening consequences Any
  • Interrupt XPOVIO.
  • Monitor hemoglobin until levels return to 8 g/dL or higher.
  • Restart XPOVIO at 1 dose level lower (see Table 1).
  • Administer blood transfusions per clinical guidelines.
Table 4: XPOVIO Dosage Modification Guidelines for Non-Hematologic Adverse Reactions
Adverse Reaction Occurrence Action
Nausea and Vomiting [see Warning and Precautions (5.3)]
Grade 1 or 2 nausea (oral intake decreased without significant weight loss, dehydration or malnutrition)OR Grade 1 or 2 vomiting (5 or fewer episodes per day) Any
  • Maintain XPOVIO and initiate additional anti-nausea medications.
Grade 3 nausea (inadequate oral caloric or fluid intake) OR Grade 3 or higher vomiting (6 or more episodes per day) Any
  • Interrupt XPOVIO.
  • Monitor until nausea or vomiting has resolved to Grade 2 or lower or baseline.
  • Initiate additional anti-nausea medications.
  • Restart XPOVIO at 1 dose level lower (see Table 1).
Diarrhea [see Warning and Precautions (5.3)]
Grade 2 (increase of 4 to 6 stools per day over baseline) 1st
  • Maintain XPOVIO and institute supportive care.
2nd and subsequent
  • Reduce XPOVIO by 1 dose level (see Table 1).
  • Institute supportive care.
Grade 3 or higher (increase of 7 stools or more per day over baseline; hospitalization indicated) Any
  • Interrupt XPOVIO and institute supportive care.
  • Monitor until diarrhea resolves to Grade 2 or lower.
  • Restart XPOVIO at 1 dose level lower (see Table 1).
Weight Loss and Anorexia [see Warning and Precautions (5.3)]
Weight loss of 10% to less than 20% OR anorexia associated with significant weight loss or malnutrition Any
  • Interrupt XPOVIO and institute supportive care.
  • Monitor until weight returns to more than 90% of baseline weight.
  • Restart XPOVIO at 1 dose level lower (see Table 1).
Hyponatremia [see Warning and Precautions (5.4)]
Sodium level 130 mmol/L or less Any
  • Interrupt XPOVIO, evaluate, and provide supportive care.
  • Monitor until sodium levels return to greater than 130 mmol/L.
  • Restart XPOVIO at 1 dose level lower (see Table 1).
Fatigue
Grade 2 lasting greater than 7 daysOR Grade 3 Any
  • Interrupt XPOVIO.
  • Monitor until fatigue resolves to Grade 1 or baseline.
  • Restart XPOVIO at 1 dose level lower (see Table 1).
Ocular Toxicity
Grade 2, excluding cataract Any
  • Perform ophthalmologic evaluation.
  • Interrupt XPOVIO and provide supportive care.
  • Monitor until ocular symptoms resolve to Grade 1 or baseline.
  • Restart XPOVIO at 1 dose level lower (see Table 1).
Grade ≥3 Any
  • Permanently discontinue XPOVIO.
  • Perform ophthalmologic evaluation.
Cataract (Grade ≥2) Any
  • Perform ophthalmologic evaluation.
  • Reduce XPOVIO by 1 dose level (see Table 1).
  • Monitor for progression.
  • Hold XPOVIO dose 24 hours prior to surgery and for 72 hours after surgery.
Other Non-Hematologic Adverse Reactions [see Warning and Precautions (5.6)]
Grade 3 or 4 Any
  • Interrupt XPOVIO.
  • Monitor until resolved to Grade 2 or lower; restart XPOVIO at 1 dose level lower (see Table 1).

All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.

This site is provided for educational and informational purposes only, in accordance with our Terms of Use, and is not intended as a substitute for the advice of a medical doctor, nurse, nurse practitioner or other qualified health professional.

Privacy Policy | Copyright © 2020. All Rights Reserved.